A subcutaneously administered investigational RNAi therapeutic (ALN-AT3) targeting antithrombin for treatment of hemophilia: interim phase 1 study results in patients with hemophilia A or B - Sorensen, B; Mant, T; Georgiev, P (J Thromb Haemost, 2015)
(abstract)